Activation of the cannabinoid receptor may have use in Systemic Sclerosis

Data presented at EULAR show that treatment of fibroblasts from systemic sclerosis patients with a cannabinoid antagonist (WIN552122) reduces TGFbeta, CTGF and collagen type-I mRNA.

Exenatide improves glycemic control in Type 2 Diabetes at one year

Data presented at ADA show that Amylin Pharmaceutical’s GLP-1 analog Exenatide continues to improve glucose control at one year in type 2 diabetes patients.

Novel series of sst2-Selective Somatostatin Antagonists

Researchers from the University of Berne, Basel and the Salk Inst have published series of sst2-Selective Somatostatin Antagonists

Epix initiate second Phase IIb trial of 5HT4 agonist PRX-03140 for Alzheimer’s disease

EPIX Pharmaceuticals have initiated a second Phase IIb trial of its 5-HT4 agonist PRX03140 in Alzheimers disease. The trial will evaluate PRX-03140 when adminstered as a monotherapy and in combination with donepezil

Researchers from the Italy publish series of Pyrrolidinylfuran Muscarinic M2 agonists

Researchers from the University of Florence, University Camerino and the Inst Sup di Sanita have published a series of Pyrrolidinylfuran Muscarinic M2 agonists

Rimonabant effective in Type 2 Diabetes

Clinical data presented at ADA show Sanofi-aventis’ CB1 antagonist rimonabant significantly improved glucose levels (as measured by HbA1c) compared to controls in patients with type 2 diabetes